You just read:

The Launch of Merck's Letermovir for Cytomegalovirus Will Transform the Treatment Paradigm for Transplant Recipients, While the Availability of a New Prophylactic Vaccine and Antibody Will Drive Growth in the Respiratory Syncytial Virus Market

News provided by

Decision Resources Group

24 Oct, 2016, 08:32 ET